Advanced Or Metastatic Triple Negative Breast Cancer clinical trials

Explore recruiting advanced or metastatic triple negative breast cancer clinical trials.

Recruiting advanced or metastatic triple negative breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Or Metastatic Triple Negative Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Treatment of advanced or metastatic triple negative breast cancer with tumor infiltrating lymphocytes (TILs).

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

"TOPOLOGY" : A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) (CAPItello-290)

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutations or RAD51-foci low test: RADIOLA TRIAL

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Advanced Or Metastatic Triple Negative Breast Cancer trials by city

Advanced Or Metastatic Triple Negative Breast Cancer in Toronto Advanced Or Metastatic Triple Negative Breast Cancer in Vancouver Advanced Or Metastatic Triple Negative Breast Cancer in Montreal Advanced Or Metastatic Triple Negative Breast Cancer in Calgary Advanced Or Metastatic Triple Negative Breast Cancer in Edmonton Advanced Or Metastatic Triple Negative Breast Cancer in Ottawa Advanced Or Metastatic Triple Negative Breast Cancer in Winnipeg Advanced Or Metastatic Triple Negative Breast Cancer in Quebec City Advanced Or Metastatic Triple Negative Breast Cancer in Hamilton Advanced Or Metastatic Triple Negative Breast Cancer in Kitchener Advanced Or Metastatic Triple Negative Breast Cancer in London Advanced Or Metastatic Triple Negative Breast Cancer in Halifax Advanced Or Metastatic Triple Negative Breast Cancer in New York Advanced Or Metastatic Triple Negative Breast Cancer in Los Angeles Advanced Or Metastatic Triple Negative Breast Cancer in Chicago Advanced Or Metastatic Triple Negative Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease